Table 2.
Expression and function of replication factor C family members in human cancers
| RFC members | Cancer type | Roles in human cancers | Reference |
|---|---|---|---|
| RFC1 | Breast cancer | Repressed by E2 in ERα-negative breast cancer cells in which ERα has been re-expressed. | Moggs et al., 2005 |
| Nasopharyngeal carcinoma | Overexpressed. | Fung et al., 2000 | |
| RFC2 | Breast cancer | Amplified. Severed as a molecular marker. | Gupte, 2015 |
| Choriocarcinoma | Increased expression. | Cui et al., 2004; Cui et al., 2003 | |
| Nasopharyngeal carcinoma | Overexpressed. Severed as a putative molecular marker. | Xiong et al., 2011 | |
| RFC3 | Acute myeloid leukemia | Overexpressed. | Hatfield et al., 2014 |
| Breast cancer | Downregulated by hsa_circ_0011946. | Zhou et al., 2018 | |
| Colorectal cancer | Mutation and loss-expression promoted cancer progression. | Kim et al., 2010 | |
| Cervical cancer cells | Upregulated by SIX homeobox 1. | Liu et al., 2014 | |
| Esophageal adenocarcinoma | Amplified and high expression predicted poor prognosis. Knockdown inhibited proliferation and anchorage independent growth. | Lockwood et al., 2012 | |
| Gastric cancer | Mutation and loss-expression promoted cancer progression. | Kim et al., 2010 | |
| Hepatocellular carcinoma | Upregulated, knockdown suppressed cell proliferation and viability and arrested the cell cycle at the S phase. | Yao et al., 2015 | |
| Ovarian carcinoma | Overexpression indicated shortened survival. Knockdown suppressed cell growth and proliferation. | Shen et al., 2014; Shen et al., 2015 | |
| Triple-negative breast cancer | Downregulated attenuated proliferation, migration and invasion via epithelial-mesenchymal transition signal pathways. Overexpression associated with poor prognosis. | He et al., 2017 | |
| RFC4 | Breast cancer | Amplification indicated reduced overall survival. | Fatima et al., 2017 |
| Cervical cancer | Overexpressed. Upregulated by SIX homeobox 1. High expression predicted poor prognosis. | Jung et al., 2009; Narayan et al., 2007; Niu et al., 2017; Zhai et al., 2007 | |
| Colon cancer | Overexpressed. | Jung et al., 2009 | |
| Gastric cancer | Overexpressed. | Jung et al., 2009 | |
| Head and neck squamous cell carcinoma | Highly expressed in HPV+ samples. | Slebos et al., 2006 | |
| Hepatocellular carcinoma | Over-expressed. Involve in cell cycle arrest and apoptosis. | Skawran et al., 2008 | |
| Lung cancer | Overexpressed. Regulated by Protein Kinase Cι. | Jung et al., 2009; Erdogan et al., 2009 | |
| Prostate cancer | Overexpressed. | Jung et al., 2009; LaTulippe et al., 2002; Barfeld et al., 2014 | |
| Skin cancer | Overexpressed. | Jung et al., 2009 | |
| RFC5 | Cervical cancer cells | Upregulated by SIX homeobox 1. | Liu et al., 2014 |
| Diffuse large B-cell lymphoma | Co-expression with DNA (cytosine-5)-methyltransferase 1 and downregulated upon its silencing. | Loo et al., 2017 | |
| Glioma | Activated by forkhead box M1. | Peng et al., 2017 | |
| Head and neck squamous cell carcinoma | Overexpressed in HPV+ samples. | Martinez et al., 2007 | |
| Prostate cancer | Overexpressed in advanced prostate tumor cells than in normal prostate cancer and early prostate tumor cells. | Barfeld et al., 2014 |